NEW YORK, NY / ACCESS Newswire / January 29, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 13.11% ...

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AUSTIN, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company ...

Cassava Sciences' Phase 3 RETHINK-ALZ trial for simufilam in Alzheimer's failed decisively, with the company discontinuing its second Phase 3 trial and reducing its workforce by 33%. The company ...

Cassava Science provided a business update. In November 2024, Cassava reported that the topline results from the Phase 3 RETHINK-ALZ study evaluating simufilam as a potential treatment for ...

Expected To Support Operations Into 2026 Conference Webcast Scheduled for Today at 8:30AM ET AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical ...

Investing.com – U.S. stocks were lower after the close on Wednesday, as losses in the Oil & Gas, Basic Materials and Technology sectors led shares lower. At the ...